
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics Holdings Inc has demonstrated promising clinical progress with the RT-810 treatment, evidenced by statistically significant improvements in glutamine levels and 15N urea, showcasing its potential efficacy with a clean safety profile. Additionally, positive trends in exploratory endpoints such as HRCT lung scans and FEV1 measures indicate beneficial responses in key patient populations, enhancing the therapeutic prospects of their pipeline candidates, including LUNAR-OTC and LUNAR-CF. The company's strong intellectual property defense strategy further bolsters its growth outlook, suggesting that Arcturus may capitalize on its innovations more effectively than anticipated.
Bears say
The financial outlook for Arcturus Therapeutics is negatively impacted by the disappointing interim data from its ARCT-032 trial, which failed to show a meaningful improvement in FEV1, leading to the removal of this asset from the company's valuation model. Furthermore, the company faces significant downside risks related to the potential delays in clinical trial initiation or enrollment for key pipeline products, along with concerns over unexpected safety issues or lower-than-expected efficacy. Lastly, the company's ability to protect its patents remains questionable, posing additional threats from increased generic competition, which has prompted a substantial reduction in the price target by financial analysts.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares